The Rolls-Royce and IAG share price rally over 35% in a day! Here’s what you need to know

Jonathan Smith notes and explores the large share price rally in both Rolls-Royce and IAG today, as the two top performing FTSE 100 stocks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today has been a very important day for stock markets around the world. We’ve seen a huge shift in risk dynamics, thanks to uncertainty being removed, along with other good news. The confirmed victory in the US election of Joe Biden allows markets to finally move on. Added to this is the news that the Pfizer vaccine is reportedly 90% effective. So far, the two largest benefactors in the FTSE 100 have been Rolls-Royce (LSE:RR) and International Consolidated Airlines Group (LSE:IAG): as I write, the Rolls-Royce share price is up around 45%. The IAG share price is up 35%.

These are some serious moves, especially when you consider the FTSE 100 is up around 5.7%. The outperformance from these two shares is large, and merits some deeper digging.

IAG share price

The rally today from IAG can really be seen to be driven from the vaccine news. The headline broke just before lunch that the Pfizer and BioNTech vaccine could have as high as a 90% effectiveness rate. The trial data is monitored by an independent data board, which adds more credibility to this. Investors were quick to think about the sector and firms that stand to gain the most from a vaccine. Quite rightly, the airline sector is definitely up there. 

The IAG share price soared higher as the possibility of a higher passenger numbers would boost profitability quicker than currently expected. Recently, former CEO Willie Walsh commented that it could take until 2023 for air travel demand to return to pre-COVID levels. Other comments along the same line is what has seen the depression in the IAG share price. Earlier this summer, the share price traded around 65p, levels not seen since 2012.

So if this vaccine comes out soon, and is genuinely effective, the air travel demand should pick up quicker than mentioned above. This should lead to a recalculation in the value of IAG, a recalculation higher in my opinion!

Rolls-Royce moving higher

I’ve written at length before about how Rolls-Royce is very sensitive to the fate of the aviation industry. Despite other troubles this year, the fall off in demand for the engines it produces for aeroplanes has been the catalyst for a large share price slump. The c.45% rally so far today still means the Rolls-Royce share price is down over 50% from the start of the year, highlighting the size of the fall.

Again the vaccine news was the key driver for the move higher in the share price. In a similar way to IAG, Rolls-Royce will benefit hugely from a vaccine given the correlation it should have to air travel demand rebounding. This should knock on to higher orders for both maintenance of existing engines and producing new engines too.

You can also argue that the “Biden Bounce” from the US election is helping the stock. President-elect Biden had good UK relations when he served in the Obama administration. This may lead to favourable trading terms for UK firms going forward. Rolls-Royce is heavily connected to the UK Government, so it’s logical to think that Rolls-Royce could do well out of any contracts made over the next four years.

jonathansmith1 has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »